Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings
AVIR·Reported November 7, 2024·After market close
Diluted EPS came in at $-0.37, beat the $-0.49 consensus by $0.12.
Diluted EPS
$-0.37beat by $0.12
Consensus: $-0.49
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Atea Pharmaceuticals, Inc.'s Q3 2024 earnings report.
Atea Pharmaceuticals, Inc. (AVIR) reported Q3 2024 earnings on November 7, 2024 after market close.
Atea Pharmaceuticals, Inc. reported diluted EPS of $-0.37 for Q3 2024.
EPS beat the consensus estimate of $-0.49 by $0.12.
You can read the 10-Q periodic report (0000950170-24-123447) directly on SEC EDGAR. The filing index links above go to sec.gov.